Paradigm Biopharmaceuticals Ltd - Asset Resilience Ratio
Paradigm Biopharmaceuticals Ltd (PAR) has an Asset Resilience Ratio of 0.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Paradigm Biopharmaceuticals Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Paradigm Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See Paradigm Biopharmaceuticals Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Paradigm Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Paradigm Biopharmaceuticals Ltd (PAR) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$71.83K | 0.31% |
| Total Liquid Assets | AU$71.83K | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Paradigm Biopharmaceuticals Ltd maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Paradigm Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Paradigm Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Paradigm Biopharmaceuticals Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Paradigm Biopharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$24.57 Million ≈ $17.39 Million |
-- |
| 2024-06-30 | 0.17% | AU$46.20K ≈ $32.69K |
AU$27.39 Million ≈ $19.38 Million |
+0.10pp |
| 2023-06-30 | 0.07% | AU$46.20K ≈ $32.69K |
AU$67.07 Million ≈ $47.46 Million |
-0.02pp |
| 2022-06-30 | 0.09% | AU$46.20K ≈ $32.69K |
AU$50.69 Million ≈ $35.87 Million |
+0.04pp |
| 2021-06-30 | 0.05% | AU$46.20K ≈ $32.69K |
AU$84.79 Million ≈ $60.00 Million |
-0.61pp |
| 2020-06-30 | 0.66% | AU$746.20K ≈ $527.98K |
AU$112.36 Million ≈ $79.50 Million |
-6.94pp |
| 2019-06-30 | 7.60% | AU$6.50 Million ≈ $4.60 Million |
AU$85.51 Million ≈ $60.50 Million |
-- |
| 2017-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$14.35 Million ≈ $10.15 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$12.35 Million ≈ $8.74 Million |
-- |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more